Blog
RSS FeedPosted by Michael Wonder on 17 Feb 2023
Mitapivat sulphate for the treatment of patients with pyruvate kinase deficiency
16 February 2023 - NICE is unable to make a recommendation on the the use of mitapivat sulphate (Pyrukynd) for the ...
Posted by Michael Wonder on 16 Feb 2023
NICE says evidence that COVID-19 treatment Evusheld is effective in protecting vulnerable adults against current variants is lacking as it announces new rapid update process for COVID-19 medicines
16 February 2023 - NICE has today issued draft guidance for public consultation which does not recommend Evusheld for preventing COVID-19 ...
Posted by Michael Wonder on 16 Feb 2023
Living health technology assessments: how close to living reality?
16 February 2023 - HTA processes have remained largely unchanged, but innovative study designs (eg, pragmatic and adaptive clinical trials, single-arm ...
Posted by Michael Wonder on 16 Feb 2023
Tixagevimab and cilgavimab for the the prevention of COVID-19 disease
16 February 2023 - The Department of Health and Social Care has NICE to produce guidance on the use of ...
Posted by Michael Wonder on 15 Feb 2023
Vutrisiran for the treatment of patients with hereditary transthyretin-related amyloidosis
15 February 2023 - NICE has published final draft guidance on the use of vutrisiran for the treatment of adults ...
Posted by Michael Wonder on 09 Feb 2023
Digital mental health tech for children and young people recommended by NICE in first rapid healthtech guidance
8 February 2023 - Four digital technologies that can help children and young people with mild to moderate symptoms of anxiety ...
Posted by Michael Wonder on 09 Feb 2023
Lorlatinib for the first-line treatment of patients with ALK positive advanced non-small-cell lung cancer
9 February 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 09 Feb 2023
Dapagliflozin propanediol monohydrate for the treatment of patients with chronic heart failure with preserved or mildly reduced ejection fraction
8 February 2023 - The Department of Health and Social Care has asked the NICE to produce guidance on the ...
Posted by Michael Wonder on 09 Feb 2023
Empagliflozin for the treatment of patients with chronic heart failure with preserved or mildly reduced ejection fraction
8 February 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 09 Feb 2023
NICE recommends genetic test to prevent newborn babies going deaf
9 February 2023 - A genetic test to establish if a newborn baby is vulnerable to deafness if treated with a ...
Posted by Michael Wonder on 09 Feb 2023
Availability of Sanofi’s Nexviadyme (avalglucosidase alfa) provides NHS with new treatment for Pompe disease
8 February 2023 - Sanofi announced today that health care specialists and patients living with Pompe disease will now have ...
Posted by Michael Wonder on 08 Feb 2023
Regorafenib monohydrate for patients with previously treated metastatic colorectal cancer
8 February 2023 - Regorafenib monohydrate is recommended as an option for the treatment of adults with metastatic colorectal cancer who ...
Posted by Michael Wonder on 08 Feb 2023
Nivolumab in combination with fluoropyrimidine- and platinum-based chemotherapy for patients with untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma
8 February 2023 - Nivolumab, when used in combination with fluoropyrimidine-based and platinum-based combination chemotherapy, is recommended as an option ...
Posted by Michael Wonder on 06 Feb 2023
Medical technology strategy
3 February 2023 - This document presents the inaugural UK medtech strategy and the timing could not be better. ...
Posted by Michael Wonder on 06 Feb 2023
Pharma industry urges halt to further rises in record revenue clawbacks
2 February 2023 - The pharmaceutical industry is calling on the government to scrap plans to raise the statutory revenue clawback ...